FDMT Debt Ratio from 2010 to 2024

FDMT Stock

USD 7.50 0.12 1.57%

4D Molecular Debt Ratio yearly trend continues to be comparatively stable with very little volatility. Debt Ratio will likely drop to 0.01 in 2024. From the period from 2010 to 2024, 4D Molecular Debt Ratio quarterly data regression had r-value of 0.62 and coefficient of variation of 49.66. View All Fundamentals

Debt Ratio

First Reported

2010-12-31

Previous Quarter

0.00926473

Current Value

0.006103

Quarterly Volatility

0.00222805

Credit Downgrade

Yuan Drop

Covid

Check 4D Molecular financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among 4D Molecular's main balance sheet or income statement drivers, such as Net Interest Income of 9.6 M, Interest Income of 9.6 M or Depreciation And Amortization of 4.2 M, as well as many indicators such as Price To Sales Ratio of 36.34, Dividend Yield of 0.0 or PTB Ratio of 2.7. FDMT financial statements analysis is a perfect complement when working with 4D Molecular Valuation or Volatility modules.

Check out the analysis of 4D Molecular Correlation against competitors.

Latest 4D Molecular's Debt Ratio Growth Pattern

Below is the plot of the Debt Ratio of 4D Molecular Therapeutics over the last few years. It is 4D Molecular's Debt Ratio historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in 4D Molecular's overall financial position and show how it may be relating to other accounts over time.

Debt Ratio

10 Years Trend

Slightly volatile

Compare to Others All Fundamentals

Debt Ratio

Timeline

FDMT Debt Ratio Regression Statistics

	Arithmetic Mean	0
	Geometric Mean	0
	Coefficient Of Variation	49.66
	Mean Deviation	0
	Median	0
	Standard Deviation	0
	Sample Variance	0.00000496
	Range	0.0067
	R-Value	0.62
	Mean Square Error	0.0000033
	R-Squared	0.38
	Significance	0.01
	Slope	0.0003
	Total Sum of Squares	0.000069

FDMT Debt Ratio History

	2024	0.006103
	2023	0.009265
	2022	0.0101

Other Fundumenentals of 4D Molecular Therapeutics

Cash Flow To Debt Ratio

4D Molecular Debt Ratio component correlations

	Total Assets	Total Stockholder Equity	Net Tangible Assets	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Net Receivables	Total Liab	Net Invested Capital	Total Current Assets	Net Working Capital	Short Term Debt	Common Stock	Property Plant Equipment	Capital Stock	Capital Surpluse	Deferred Long Term Liab
Total Assets		0.23	0.96	-0.56	-0.98	-0.84	0.93	0.31	0.42	0.98	1.0	0.99	0.8	0.97	0.86	0.97	0.82	0.84
Total Stockholder Equity	0.23		0.28	-0.13	-0.29	-0.36	-0.01	0.36	-0.39	0.22	0.26	0.31	0.36	0.31	0.12	0.34	0.2	0.12
Net Tangible Assets	0.96	0.28		-0.64	-0.97	-0.86	0.88	0.19	0.34	0.97	0.96	0.95	0.81	0.95	0.88	0.96	0.82	0.84
Current Deferred Revenue	-0.56	-0.13	-0.64		0.51	0.85	-0.64	0.26	-0.06	-0.59	-0.52	-0.52	-0.78	-0.64	-0.85	-0.66	-0.91	-0.9
Net Debt	-0.98	-0.29	-0.97	0.51		0.82	-0.89	-0.36	-0.41	-0.95	-0.98	-0.97	-0.79	-0.92	-0.83	-0.93	-0.75	-0.77
Retained Earnings	-0.84	-0.36	-0.86	0.85	0.82		-0.83	-0.2	-0.09	-0.82	-0.82	-0.83	-0.98	-0.89	-0.92	-0.91	-0.95	-0.93
Accounts Payable	0.93	-0.01	0.88	-0.64	-0.89	-0.83		0.11	0.59	0.89	0.91	0.87	0.79	0.87	0.93	0.87	0.86	0.9
Net Receivables	0.31	0.36	0.19	0.26	-0.36	-0.2	0.11		-0.26	0.19	0.35	0.42	0.3	0.27	-0.05	0.27	-0.03	-0.06
Total Liab	0.42	-0.39	0.34	-0.06	-0.41	-0.09	0.59	-0.26		0.37	0.41	0.31	0.02	0.23	0.43	0.22	0.22	0.32
Net Invested Capital	0.98	0.22	0.97	-0.59	-0.95	-0.82	0.89	0.19	0.37		0.97	0.97	0.75	0.98	0.84	0.97	0.81	0.84
Total Current Assets	1.0	0.26	0.96	-0.52	-0.98	-0.82	0.91	0.35	0.41	0.97		0.99	0.78	0.96	0.83	0.96	0.78	0.81
Net Working Capital	0.99	0.31	0.95	-0.52	-0.97	-0.83	0.87	0.42	0.31	0.97	0.99		0.8	0.97	0.8	0.97	0.78	0.79
Short Term Debt	0.8	0.36	0.81	-0.78	-0.79	-0.98	0.79	0.3	0.02	0.75	0.78	0.8		0.85	0.87	0.87	0.89	0.87
Common Stock	0.97	0.31	0.95	-0.64	-0.92	-0.89	0.87	0.27	0.23	0.98	0.96	0.97	0.85		0.85	1.0	0.87	0.87
Property Plant Equipment	0.86	0.12	0.88	-0.85	-0.83	-0.92	0.93	-0.05	0.43	0.84	0.83	0.8	0.87	0.85		0.86	0.94	0.97
Capital Stock	0.97	0.34	0.96	-0.66	-0.93	-0.91	0.87	0.27	0.22	0.97	0.96	0.97	0.87	1.0	0.86		0.88	0.88
Capital Surpluse	0.82	0.2	0.82	-0.91	-0.75	-0.95	0.86	-0.03	0.22	0.81	0.78	0.78	0.89	0.87	0.94	0.88		0.99
Deferred Long Term Liab	0.84	0.12	0.84	-0.9	-0.77	-0.93	0.9	-0.06	0.32	0.84	0.81	0.79	0.87	0.87	0.97	0.88	0.99

Click cells to compare fundamentals

About 4D Molecular Financial Statements

4D Molecular shareholders use historical fundamental indicators, such as Debt Ratio, to determine how well the company is positioned to perform in the future. Although 4D Molecular investors may analyze each financial statement separately, they are all interrelated. The changes in 4D Molecular's assets and liabilities, for example, are also reflected in the revenues and expenses on on 4D Molecular's income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.

	Last Reported	Projected for Next Year
Debt Ratio	0.01	0.01
Cash Flow To Debt Ratio	(24.07)	(25.27)

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for FDMT Stock Analysis

When running 4D Molecular's price analysis, check to measure 4D Molecular's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy 4D Molecular is operating at the current time. Most of 4D Molecular's value examination focuses on studying past and present price action to predict the probability of 4D Molecular's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move 4D Molecular's price. Additionally, you may evaluate how the addition of 4D Molecular to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

FDMT Debt Ratio from 2010 to 2024

Latest 4D Molecular's Debt Ratio Growth Pattern

FDMT Debt Ratio Regression Statistics

FDMT Debt Ratio History

Other Fundumenentals of 4D Molecular Therapeutics

4D Molecular Debt Ratio component correlations

About 4D Molecular Financial Statements

Thematic Opportunities

Explore Investment Opportunities

Additional Tools for FDMT Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY